^
Association details:
| Biomarker: | NOTCH1 mutation |
|---|---|
| Cancer: | T Acute Lymphoblastic Leukemia |
| Drug: | prednisone (Steroid receptor agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols
Excerpt:
...For 23 patients, the in vivo prednisone response was known. NOTCH1-activated patients were correlated with a good in vivo prednisone response as 14 out of 16 patients with an initial PGR contained NOTCH1 mutations, in contrast to 2 out of 7 cases with a poor response (P=0.01). This observation was stronger by including FBXW7 data where 15 out of 16 cases with a PGR had a NOTCH1/FBXW7 mutation in contrast to only 2 out of 7 prednisone poor response cases (P=0.003)...
DOI:
https://doi.org/10.1038/leu.2010.204
Source:
Title:
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
Excerpt:
The presence of NOTCH1 mutations was significantly correlated with a good prednisone response and favorable minimal residual disease (MRD) kinetics, which was independent from sex, age, white blood cell count, and T-cell immunophenotype at the time of diagnosis.
DOI:
10.1182/blood-2005-12-4956
